Latest News
Press Releases
- 02.11.08 - Horizon Therapeutics Completes Enrollment in Phase 3 for Trials for Lead Product Candidate HZT-501
- 10.08.07 - Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
- 07.23.07 - Horizon Therapeutics Completes $30 Million Equity Financing to Advance Pipeline of "GI-friendly" NSAIDS for Mild-to-Moderate Pain
- 03.27.07 - Horizon Therapeutics Begins Patient Enrollment in Phase 3 Trials For "GI-Friendly" NSAID
- 01.08.07 - Horizon Therapeutics announces Special Protocol Assessment with FDA for Phase 3 trial program
- 01.04.07 - Horizon Therapeutics completes $21 million in equity financing to advance pipeline of "GI-friendly" NSAIDs for mild-to-moderate pain